Press Releases
iCAD Reports Financial Results for First Quarter Ended March 31, 2022
Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – May 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022. Highlights:…
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Clinical and IT Experts from Wake Radiology
Leading healthcare provider with 14 imaging centers in North Carolina identified ProFound AI as the premier solution in a competitive trial based on unique workflow benefits and multivendor flexibility NASHUA, N.H. – April 28, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection…
iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11
NASHUA, N.H. – April 27, 2022 – iCAD®, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM…
iCAD Announces Significant Commercial Momentum for ProFound AI® Among Customers Equipped with the Leading Provider of 3D Mammography Systems
Customers report continued workflow advantages and clinical superiority with iCAD’s suite of AI-powered breast health solutions, compared to other available breast AI solutions NASHUA, N.H. – April 26, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced significant…
iCAD Announces Estimated Q1 Revenue and Upcoming Board and CFO Transitions
Company expects preliminary estimated revenue to be $7.5 million Timothy Norris Irish Appointed Chairman of the Board of Directors, Successor CFO search underway NASHUA, N.H. – April 21, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported…
iCAD Launches ProFound Insights, ProFound Impact Webinar Series on April 27
First event to feature Kettering Health, a leading enterprise breast care provider with 14 breast centers across southwest Ohio NASHUA, N.H. – April 19, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will launch a…
iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment
Multiple leading institutions leverage the versatility of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancers NASHUA, N.H. – April 5, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that additional patients have been treated under…
iCAD Highlights Breast Health AI Platform at the 2022 Healthcare Information and Management Systems Society (HIMSS) Meeting
World-leading breast cancer AI solutions featured for demonstration in iCAD booth NASHUA, N.H., March 14, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of Breast AI solutions, including ProFound AI® for Digital…
iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual Conference
iCAD’s award winning portfolio of breast health solutions to be featured at inaugural Pink Paradigm Summit, uniting clinical and advocacy leadership NASHUA, N.H., March 10, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing…
iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference
NASHUA, N.H., March 9, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 32nd Annual Oppenheimer Healthcare Conference, taking place March 15-17, 2022. Stacey Stevens, President and CEO of iCAD, Inc. is…